Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report 2026

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview

• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size has reached to $2.27 billion in 2025 • Expected to grow to $3.32 billion in 2030 at a compound annual growth rate (CAGR) of 7.8% • Growth Driver: Rising Healthcare Expenditure Driving Market Growth • Market Trend: Breakthroughs In Immune Modulation For The Market • North America was the largest region in 2025.

What Is Covered Under Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder that causes progressive weakness and impaired sensory function due to nerve inflammation and demyelination. It results from the immune system attacking the myelin sheath of peripheral nerves, leading to muscle weakness, numbness, and coordination issues. The main treatment types of chronic inflammatory demyelinating polyneuropathy (CIDP) are intravenous immunoglobulin, corticosteroids, plasmapheresis, physiotherapy, and others. Intravenous immunoglobulin (IVIg) is a blood product made from pooled human plasma that contains antibodies used to treat autoimmune conditions, immune deficiencies, and inflammatory diseases by modulating the immune system. These treatments are administered via various routes, including intravenous, oral, and others, and diagnosis typically involves electrodiagnostic testing, nerve conduction studies, electromyography (EMG), spinal fluid analysis, and other diagnostic procedures. Distribution channels for these treatments include hospitals, pharmacies, online pharmacies, and specialty clinics, with end users primarily consisting of hospitals, research institutions, and homecare settings.

What Is The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Forecast?

The chronic inflammatory demyelinating polyneuropathy (cidp) market size is expected to see strong growth in the next few years. It will grow to $3.32 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing development of targeted immunotherapies, rising focus on minimizing treatment side effects, expansion of remote patient monitoring, growing demand for sustained remission therapies, increasing investments in rare disease research. Major trends in the forecast period include increasing use of ivig as first-line therapy, rising adoption of personalized treatment regimens, growing integration of advanced diagnostic tools, expansion of home-based treatment models, enhanced focus on long-term disease management.

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segmentation

1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments 2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administrations 3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis 4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics 5) By End User: Hospitals, Research Institutions, Homecare Settings Subsegments: 1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy 2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids 3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis 4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy 5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies

What Is The Driver Of The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?

The increasing healthcare expenditure is expected to propel the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market going forward. Rising healthcare expenditure is driven by increased investments in medical infrastructure, growing demand for advanced treatments, expanded insurance coverage, and government efforts to enhance healthcare accessibility. High healthcare expenditure enhances access to advanced treatments, early diagnosis, and better management of CIDP, improving patient outcomes and quality of life. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth observed in 2022. Therefore, the increasing healthcare expenditure is driving the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) industry.

Key Players In The Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

Major companies operating in the chronic inflammatory demyelinating polyneuropathy (cidp) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Hualan Biological Engineering Inc, argenx SE, Bio Products Laboratory Ltd., Kedrion S.p.A, Biotest AG, Hansa Biopharma AB, UCB SA, Teva Pharmaceutical Industries Ltd, Merck & Co Inc, Roche Holding AG, Biogen Inc, Momenta Pharmaceuticals, Teijin Pharma Limited, Sanquin Plasma Products BV, Fresenius Kabi AG, Immunovant Sciences GmbH, Akari Therapeutics Plc, GeNeuro Pharmaceuticals, MedDay Pharmaceuticals, HanAll Pharma

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends and Insights

Major companies operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are focusing on advancements such as intravenous immunoglobulin (IVIG) therapy to enhance treatment efficacy, improve patient outcomes, and provide more targeted and efficient immune modulation for managing CIDP. Intravenous immunoglobulin (IVIG) therapy is a treatment that involves infusing concentrated antibodies from healthy donors to help modulate the immune system and reduce inflammation in autoimmune conditions. For instance, in January 2024, Takeda Pharmaceutical Company Limited, a Japan-based biopharmaceutical company, announced FDA approval for GAMMAGARD LIQUID as an intravenous immunoglobulin (IVIG) therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This approval allows its use as an induction therapy, starting with an initial dose followed by maintenance doses to support long-term disease management and improve neuromuscular function.

What Are Latest Mergers And Acquisitions In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?

In November 2024, Zai Lab Limited, a China-based biopharma company, partnered with argenx SE to introduce VYVGART Hytrulo as the first approved subcutaneous injection for chronic inflammatory demyelinating polyneuropathy (CIDP) in China. This collaboration aims to provide a convenient, effective, and well-tolerated treatment to address unmet medical needs and enhance patient outcomes. argenx SE is a Netherlands-based biotechnology company dedicated to advancing innovative therapies for severe autoimmune diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP).

Regional Outlook

North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?

The chronic inflammatory demyelinating polyneuropathy (CIDP) market consists of revenues earned by entities by providing services such as diagnostic testing, patient management, and therapeutic treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic inflammatory demyelinating polyneuropathy (CIDP) market also includes sales of plasma exchange devices, monoclonal antibodies, nerve conduction study equipment, and physical therapy aids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report 2026?

The chronic inflammatory demyelinating polyneuropathy (cidp) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chronic inflammatory demyelinating polyneuropathy (cidp) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.